Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

34.12 +2.75 (+8.77%)
Streaming Delayed Price Updated: 3:04 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
From The Rosen Law Firm, P.A.
Via Business Wire
Harrow Launches Next-Generation Compounded Atropine Formulations
From Harrow
Via Business Wire
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
From Harrow
Via Business Wire
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
From Harrow
Via Business Wire
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
From Harrow Health, Inc.
Via Business Wire
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Secures Capital to Close Recently Announced Acquisition
From Harrow Health, Inc.
Via Business Wire
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
From Harrow Health, Inc.
Via Business Wire
Harrow Prices $25 Million Offering
From Harrow
Via Business Wire
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
From Harrow
Via Business Wire
Harrow and iOR Partners Expand National Product Supply Agreement
From Harrow
Via Business Wire
Harrow Announces Third Quarter 2022 Financial Results
From Harrow
Via Business Wire
Harrow Launches Atropine.com
From Harrow
Via Business Wire
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
From Harrow
Via Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Sells Non-Ophthalmic Compounding Business
From Harrow
Via Business Wire
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
From Harrow
Via Business Wire
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
From Harrow
Via Business Wire
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces Second Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces First Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
From Harrow Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.